http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이동섭,김준모,우경인,장혜란,Dong Sub Lee,Joon Mo Kim,Kyung In Woo,Hae Ran Chang 대한안과학회 2006 대한안과학회지 Vol.47 No.9
Purpose: To determine postoperative astigmatic changes after surgery for congenital ptosis and the astigmatic changes depending on surgical method and to discern cases of postoperatively developed anisometropia or amblyopia. Methods: Fifty-one patients who underwent surgery due to congenital ptosis were reviewed. Refraction or cycloplegic refraction was conducted preoperatively and 3 to 6 months after surgery to measure astigmatic changes. Astigmatic changes in operated eyes were compared to control eyes. Astigmatic changes were compared depending on surgical method. Results: The mean astigmatism was 1.33±1.29D preoperatively and 1.48±1.13D postoperatively (P=0.10) and the mean astigmatic change in the ptotic and control eye was an increase in cylinder +0.56±0.55D and +0.68±0.72D (P=0.37). The mean astigmatic change of patients receiving frontalis sling was +0.57±0.67D which was similar to those who received levator resection (+0.56±0.50D). Newly developed anisometropia was found in three patients postoperatively due to an increase in astigmatism, but newly developed amblyopia was not found. Conclusions: The increase of astigmatism by ptosis surgery was not statistically significant and there was no statistically significant difference when accounting for surgical method. However, it is necessary to monitor refractive error carefully in younger patients to prevent amblyopia because postoperative increase of astigmatism can cause anisometropia.
( Hae Lim Lee ),( Sung Won Lee ),( Nam Ik Han ),( Hee Yeon Kim ),( Chang Wook Kim ),( Chan Ran You ),( Sang Wook Choi ),( Se Hyun Cho ),( Joon-yeol Han ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: The advent of direct-acting antiviral agents (DAA) has enabled high sustained viral response (SVR) rates in hepatitis C virus (HCV) infected patients. We aimed to evaluate longitudinal changes in liver function parameters and fibrosis scores in patients who achieved SVR. Methods: A total of 963 patients who received interferon free DAA combination ± ribavirin for HCV infection between December 2015 and February 2017 at the liver unit of the Catholic University of Korea were consecutively recruited. Patients with hepatocellular carcinoma, other liver diseases, or those who received liver transplantation were excluded. Four hundred and thirteen patients who achieved sustained viral response 12 weeks post treatment (SVR12) were analyzed and the parameters of liver function, AST to Platelet Index (APRI) and Fibrosis-4 (FIB-4) scores before treatment was compared to that of SVR12. Results: Of the 413 patients, 308 (75%) patients had chronic hepatitis and 105 (25%) patients had liver cirrhosis. In the total patients, aspartate aminotransferase were decreased from 61 to 28 IU/L and alanine aminotransferase levels were decreased from 57 to 21 IU/L between baseline and 4 weeks post treatment (p<0.001, both). In the patients with chronic hepatitis, APRI and FIB-4 scores were all significantly improved; APRI score was 0.93±1.28 and 0.51±0.56, p<0.001, FIB-4 score was 3.25±3.79 and 2.67±2.21, p=0.022, (mean±SD), at baseline and SVR12, respectively. In the patients with liver cirrhosis, platelet (PLT), albumin, prothrombine time international normalized ratio (PT INR) levels, APRI and FIB-4 scores were all significantly improved; PLT level was 115±53 and 166±82, p<0.001, albumin level was 3.8±0.6 and 4.3±0.3, p<0.001, PT INR level was 1.15±0.13 and 1.05±0.09, p<0.001, APRI score was 2.13±1.59 and 0.55±0.42, p<0.001, FIB-4 score was 7.83±5.56 and 2.79±1.73, p<0.001, at baseline and SVR12, respectively (mean±SD). Conclusions: This study suggested that a significant improvement in liver function parameters and non-invasive fibrosis markers could be achieved in HCV infected patients who achieved SVR.
Hypomorphic Mutations in <i>TONSL</i> Cause SPONASTRIME Dysplasia
Chang, Hae Ryung,Cho, Sung Yoon,Lee, Jae Hoon,Lee, Eunkyung,Seo, Jieun,Lee, Hye Ran,Cavalcanti, Denise P.,Mä,kitie, Outi,Valta, Helena,Girisha, Katta M.,Lee, Chung,Neethukrishna, Kausthubham,Bhava Elsevier 2019 American journal of human genetics Vol.104 No.3
<P>SPONASTRIME dysplasia is a rare, recessive skeletal dysplasia characterized by short stature, facial dysmorphism, and aberrant radiographic findings of the spine and long bone metaphysis. No causative genetic alterations for SPONASTRIME dysplasia have yet been determined. Using whole-exome sequencing (WES), we identified bi-allelic <I>TONSL</I> mutations in 10 of 13 individuals with SPONASTRIME dysplasia. TONSL is a multi-domain scaffold protein that interacts with DNA replication and repair factors and which plays critical roles in resistance to replication stress and the maintenance of genome integrity. We show here that cellular defects in dermal fibroblasts from affected individuals are complemented by the expression of wild-type <I>TONSL</I>. In addition, <I>in vitro</I> cell-based assays and <I>in silico</I> analyses of TONSL structure support the pathogenicity of those <I>TONSL</I> variants. Intriguingly, a knock-in (KI) <I>Tonsl</I> mouse model leads to embryonic lethality, implying the physiological importance of TONSL. Overall, these findings indicate that genetic variants resulting in reduced function of TONSL cause SPONASTRIME dysplasia and highlight the importance of TONSL in embryonic development and postnatal growth.</P>
B 형 간염백신의 효과 - 접종부위에 따른 면역성의 차이 -
이창홍(Chang Hong Lee),박영태(Young Tae Park),유혜경(Hae Kyoung Yoo),이명석(Myung Seok Lee),문해란(Hae Ran Moon) 대한내과학회 1987 대한내과학회지 Vol.32 No.4
N/A The efficacy of a highly purified, formalin inactivated hepatitis B vaccine (Hepavax-B®), 20ug of surface antigen (HBsAg), given at 0, 1, and 6 months, was evaluated in 83 healthy young volunteers (mean age;25 years old) according to the injection sites of vaccine. All three doses had been given by arm injections in 51 subjects (A group) and the remainders (22 subjects) had received buttock injections for the first 2 doses followed by third-dose arm injections (B group). A significant decrease in seroconversion was noted 6 months after first dose injections in B group male subjects (31%) comparing with B group females and A group males and females, but conversion rate was rapidly elevated (95%) shortly after third-dose arm injections in these subjects. Geometrical mean antibody levels expressed as ratio units (RU) were significantly low 6 months after first dose injections in B group (both female % male) (p<0.005 vs. A group). This difference between A & B group was disappeared by the rapid increase of antibody level in B group subjects 2 months after third-dose injections, but in comparison with females, mean antibody level of male subjects was still significantly low in B group (p<0.005). Overall antibody conversion rates were over 95%, and antibody levels were above 10 RU in 90% of responders in both A & B groups 2 months after third-dose injections. Subjects with antibody levels above 100 RU were 65% in A group responders at the same time. In conclusion, as a method of hepatitis B vaccination, arm seems to be a superior site of injection to buttock even in young persons whose expected antibody responses are known to be excellent.